Basics

How to Read Peptide Data

Before you compare peptides, it is worth understanding where the statuses and numbers in their profiles come from. This explainer shows how to tell preclinical evidence from clinical, read dosages without illusions, and spot the line where science ends and marketing begins.

PeptideWiki Editorial~7 min

Why the status comes first

Research status is the first thing worth reading in a peptide profile — and the easiest thing to skip. It is not a good-or-bad rating and not a mark of quality. A status states exactly one thing: how far the study of a compound has progressed, and in what context its data were obtained.

Two peptides can look equally promising in a short description. Yet behind one stand decades of human observation and registered medical use, while behind the other there is a single experiment on a cell culture. Read the status first, and everything else on the page reads differently: promises become hypotheses, and "it works" becomes "it is being studied".

That is why every PeptideWiki profile carries the status at the very top of the page, right next to the compound's name. Our job is not to convince you that a substance is helpful or harmful, but to show how solid the ground is beneath each specific claim.

A status is not a judgement of the compound — it is an honest note on how much we actually know. That is the PeptideWiki principle: data without embellishment.

What the four statuses mean

Profiles use four statuses. They describe different stages of the road from an idea to confirmed use. None of them means "safe" or "effective for you" — they speak about the maturity of the evidence, not about the outcome for a particular person.

Approved

A regulator has authorised the use of the compound for a specific indication, in a specific form, for a specific group of people. Approval is always narrow: "approved for one thing" does not mean "approved for everything" — and the status can differ between countries. This group includes, for example, semaglutide and other prescription drugs.

Clinical Trial

The compound has been studied in humans in controlled trials. Human data exist, but they may come from an early phase, a small sample, or a narrow indication. Having clinical data is not the same as "proven for your goal".

Preclinical

The evidence rests on cell and animal experiments. Such results are hypotheses about humans, not conclusions about them. Many of the most discussed research peptides — BPC-157 among them — sit exactly here.

Experimental

There is almost no systematic data: theory, scattered reports, or vendors' claims. This is the zone of maximum uncertainty, where it is easiest to mistake hope for fact.

Preclinical and clinical are not the same

The most common mistake in reading the data is carrying a result from animals straight over to humans. "Accelerates healing in rats" sounds convincing, but between that sentence and a benefit for humans lie several fundamental gaps.

Why results do not transfer directly

  • Doses do not scale linearly. Converting "by body weight" from mouse to human is almost always wrong — metabolism and body surface area change the picture.
  • Metabolism differs. Breakdown rates, receptors and clearance pathways vary between species, so an effect can weaken, vanish or turn into something else.
  • Laboratory conditions are artificial. Animals are infected, injured or genetically modified so that an effect can be seen — real people do not fit these models.
  • The endpoints are different. A marker in a test tube is not how a person feels, performs, or how long they live.
  • Successes get published more often. Negative results reach print less often, so the picture drawn by a single study looks rosier than it is.

None of this makes preclinical data useless. They are an essential first step that suggests what to study next. But that step is an invitation to research — not its conclusion.

How to read dosages and protocols

The dosage figures in profiles and protocols are what the sources describe, not what we advise anyone to take. A protocol records what was done, and how, in a specific study or practice; it does not become an instruction merely because it is written next to a compound's name.

What to check when you meet a dose

  • The units. Micrograms (mcg) and milligrams (mg) differ a thousandfold — confusing them is dangerous.
  • Who the data come from. A range measured in animals cannot be quietly transferred to humans.
  • Where the number comes from. A figure should have a primary source, not a forum retelling.
  • What the range means. A spread of values is uncertainty, not a menu to choose from.

Where the data come from

Not all sources are equal. It helps to keep a rough hierarchy of evidence in mind — from the most reliable to the weakest. The higher an item stands on the list, the smaller the chance that its conclusion falls apart under scrutiny.

  1. Systematic reviews and meta-analyses — they pool many studies and stand above everything else.
  2. Randomised controlled trials (RCTs) — experiments on humans with a control group.
  3. Observational studies — cohorts and before/after comparisons, where coincidence is harder to rule out.
  4. Case reports — interesting, but by themselves they prove nothing.
  5. Preclinical data — cells and animals: a hypothesis, not a confirmation.
  6. Anecdotes and testimonials — forums and personal experience: the weakest ground of all.

It is also worth telling apart a peer-reviewed publication, a preprint (not yet peer-reviewed), a vendor's page and a forum thread. To check a loud claim, find the primary source, look at the sample size, and note who funded the work. Unfamiliar terms are briefly explained in the glossary.

Marketing red flags

Science sounds cautious; marketing sounds confident. A few signs help you tell a sales pitch from data before you even reach the sources.

  • A guaranteed result and a promise of "no side effects".
  • "Clinically proven" — without a single reference to a study.
  • Before-and-after photos instead of measurable data.
  • One universal dosage "for everyone".
  • Testimonials and success stories placed above numbers and methodology.
  • Artificial urgency: "almost sold out", "today only".

In short: a reader's checklist

Strip everything down to the essentials, and reading peptide data comes down to a few habits.

  • Look at the status before the promises.
  • Ask who the data come from — cells, animals or humans.
  • Find the primary source of a number, not a retelling of it.
  • Check the units and the context of every dosage.
  • Keep "being studied" apart from "proven".
  • Be wary of any claim with no reference next to it.

Sources

Below are the databases and registries that make it easy to verify statuses and primary sources. References to specific studies live inside each peptide's profile in the catalogue.

  1. 01
    PubMed

    the U.S. National Library of Medicine's database of peer-reviewed biomedical publications; the starting point for finding primary sources.

  2. 02
    Cochrane

    systematic reviews and meta-analyses: the top of the evidence hierarchy.

  3. 03
    ClinicalTrials.gov

    the registry of clinical trials: phase, status, indications and participants.

  4. 04
    DailyMed

    official labelling of drug products approved by the FDA in the United States.

  5. 05
    EMA — Medicines

    regulatory statuses and approved indications in the European Union.

  6. 06
    WHO — International Nonproprietary Names (INN)

    unified compound names that keep you from getting lost among synonyms and trade names.